Area of research
Endocrinology, Diabetes and Metabolism · Hepatology
Research interest
Research interests include Thyroid Cancer Diagnosis and Treatment, Thyroid Disorders and Treatments, Hepatocellular Carcinoma Treatment and Prognosis, and Thyroid and Parathyroid Surgery.
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy
Systemic Therapy for Hepatocellular Carcinoma: Chinese Consensus-Based Interdisciplinary Expert Statements
Apatinib versus placebo in patients with locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: Post hoc analyses from the REALITY randomized clinical trial.
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel
P2.04-025 Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study
Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study
Phase III Study of Apatinib in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial